HLS Therapeutics Inc is a pharmaceutical company that provides life science products.
Its pharmaceutical products treat issues related to the cardiovascular specialities and central nervous system.
The product pipeline includes the following drugs:
Clozaril: It is used to treat Schizophrenia. The drug was acquired in 2015 and is marketed in the United States and Canada.
Royalty Portfolio: It is a globally marketed product acquired by HLS Therapeutics in 2020.
Mycare Insite: It is a psychiatry/diagnostic drug at a pre-filing stage. The company will distribute in Canada.
Perseris: It is a drug for Schizophrenia whose submission is yet under review, the company says. The drug got licensed in 2019 and will be marketed in Canada alone.
Trinomia: It was in-license in 2017, and its submission is under review. Trinomia is meant for treating cardiovascular risk reduction.
CSAN Pronto: The drug was approved in 2019 and is presently marketed in Canada. It is meant for WBV Point-of-care diagnosis.
Vascepa: In September 2017, the company licensed the rights to distribute the product in Canada commercially.
In February 2019, the company filed the Athlas One Point-of-Care diagnostic device in Canada under CSAN Pronto's name. The company reportedly focuses on new opportunities in the pharmaceutical market to strengthen its commercial portfolio.
The pharmaceutical company aims to acquire products and therapies in the pre-commercial or commercial stage. Its future acquisitions are focused on North American markets and two therapeutic areas of CNS and cardiovascular diseases.
The various firms that provide analyst coverage to the firm include Stifel Canada, Clarus Securities Inc, Raymond James Ltd, iA Securities, Bloom, Burton & Co and Canaccord Genuity Corp.
The company introduces novel therapies and aims at maintaining a portfolio of branded drugs in the healthcare market. The specialty drug manufacturer has active operations in Toronto, Montreal, and Philadelphia.
HLS Therapeutics sources its products from the originator of the drugs or the in-class manufacturing partners, which ensures the quality of its brands and manufacturing process reportedly. In addition, the pharmaceutical company claims to comply with the mandates and regulations by Health Canada and the FDA.